CH678013A5 - - Google Patents

Download PDF

Info

Publication number: CH678013A5
Authority: CH; Switzerland
Prior art keywords: group; gnrh; carbon atoms; analogs; amino acid
Prior art date: 1988-05-10

Application number

CH1725/89A

Other languages

German (de)

English (en)

Inventor

Gyoergy Dr Keri

Robert I Dr Nicholson

Istvan Dr Teplan

Tamas Gulyas

Aniko Dr Horvath

Gyoergyi Dr-Major Boekoenyi

Balazs Dr Szoeke

Agnes Balogh

Orsolya Dr Csuka

Original Assignee

Innofinance Altalanos Innovaci

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-05-10

Filing date

1989-05-08

Publication date

1991-07-31

1989-05-08 Application filed by Innofinance Altalanos Innovaci filed Critical Innofinance Altalanos Innovaci

1991-07-31 Publication of CH678013A5 publication Critical patent/CH678013A5/de

Links

108050000048 Gonadoliberin Proteins 0.000 claims description 8
102000009165 Gonadoliberin Human genes 0.000 claims description 8
230000000259 anti-tumor effect Effects 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 7
239000000825 pharmaceutical preparation Substances 0.000 claims description 6
150000008575 L-amino acids Chemical group 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
239000002184 metal Chemical class 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
150000008574 D-amino acids Chemical group 0.000 claims description 2
125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 description 23
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 19
238000011282 treatment Methods 0.000 description 17
229940088597 hormone Drugs 0.000 description 15
239000005556 hormone Substances 0.000 description 15
210000004027 cell Anatomy 0.000 description 13
206010006187 Breast cancer Diseases 0.000 description 12
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 12
210000001672 ovary Anatomy 0.000 description 12
208000026310 Breast neoplasm Diseases 0.000 description 11
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 11
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 11
150000001875 compounds Chemical class 0.000 description 11
230000000694 effects Effects 0.000 description 11
229940028334 follicle stimulating hormone Drugs 0.000 description 11
230000001419 dependent effect Effects 0.000 description 10
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 10
230000016087 ovulation Effects 0.000 description 10
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
238000000586 desensitisation Methods 0.000 description 7
230000010534 mechanism of action Effects 0.000 description 7
230000009467 reduction Effects 0.000 description 7
241000251468 Actinopterygii Species 0.000 description 6
206010062767 Hypophysitis Diseases 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
230000006870 function Effects 0.000 description 6
210000003635 pituitary gland Anatomy 0.000 description 6
239000000186 progesterone Substances 0.000 description 6
229960003387 progesterone Drugs 0.000 description 6
235000019688 fish Nutrition 0.000 description 5
210000004907 gland Anatomy 0.000 description 5
230000035800 maturation Effects 0.000 description 5
150000003431 steroids Chemical class 0.000 description 5
230000004614 tumor growth Effects 0.000 description 5
NMJREATYWWNIKX-XJIZABAQSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 NMJREATYWWNIKX-XJIZABAQSA-N 0.000 description 4
WPKQYFUSPONRAT-BXXNOCLASA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-5-amino-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hy Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 WPKQYFUSPONRAT-BXXNOCLASA-N 0.000 description 4
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 4
102000006771 Gonadotropins Human genes 0.000 description 4
108010086677 Gonadotropins Proteins 0.000 description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
238000011161 development Methods 0.000 description 4
229930182833 estradiol Natural products 0.000 description 4
230000003325 follicular Effects 0.000 description 4
239000002622 gonadotropin Substances 0.000 description 4
229940094892 gonadotropins Drugs 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
239000003270 steroid hormone Substances 0.000 description 4
241000287828 Gallus gallus Species 0.000 description 3
239000000556 agonist Substances 0.000 description 3
210000002149 gonad Anatomy 0.000 description 3
230000003054 hormonal effect Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
230000027272 reproductive process Effects 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
108010069236 Goserelin Proteins 0.000 description 2
102000008238 LHRH Receptors Human genes 0.000 description 2
108010021290 LHRH Receptors Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000002710 gonadal effect Effects 0.000 description 2
230000001456 gonadotroph Effects 0.000 description 2
230000012010 growth Effects 0.000 description 2
238000010562 histological examination Methods 0.000 description 2
210000003016 hypothalamus Anatomy 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000021616 negative regulation of cell division Effects 0.000 description 2
230000001817 pituitary effect Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
229960003604 testosterone Drugs 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
102000005606 Activins Human genes 0.000 description 1
108010059616 Activins Proteins 0.000 description 1
206010060999 Benign neoplasm Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000005243 Chondrosarcoma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
102000008175 FSH Receptors Human genes 0.000 description 1
108010060374 FSH Receptors Proteins 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
102100033467 L-selectin Human genes 0.000 description 1
102000023108 LH Receptors Human genes 0.000 description 1
108010011942 LH Receptors Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108010085012 Steroid Receptors Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
206010003883 azoospermia Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
102000015694 estrogen receptors Human genes 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
210000001752 female genitalia Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
125000001998 leucyl group Chemical group 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000000938 luteal effect Effects 0.000 description 1
230000029849 luteinization Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
208000008634 oligospermia Diseases 0.000 description 1
230000036616 oligospermia Effects 0.000 description 1
231100000528 oligospermia Toxicity 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000003578 releasing effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
208000012201 sexual and gender identity disease Diseases 0.000 description 1
208000015891 sexual disease Diseases 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
102000005969 steroid hormone receptors Human genes 0.000 description 1
230000010009 steroidogenesis Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
125000001982 tryptophyl group Chemical group 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)

CH1725/89A 1988-05-10 1989-05-08 CH678013A5 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU882347A HU199694B (en)	1988-05-10	1988-05-10	Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives

Publications (1)

Publication Number	Publication Date
CH678013A5 true CH678013A5 (fr)	1991-07-31

Family

ID=10958948

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH1725/89A CH678013A5 (fr)	1988-05-10	1989-05-08

Country Status (16)

Country	Link
JP (1)	JPH0215097A (fr)
KR (1)	KR900017610A (fr)
BE (1)	BE1004932A3 (fr)
CH (1)	CH678013A5 (fr)
DE (1)	DE3915317A1 (fr)
DK (1)	DK228289A (fr)
FI (1)	FI892275A7 (fr)
FR (1)	FR2631237A1 (fr)
GB (1)	GB2218335B (fr)
GR (1)	GR890100315A (fr)
HU (1)	HU199694B (fr)
IL (1)	IL89998A0 (fr)
IT (1)	IT1229251B (fr)
LU (1)	LU87516A1 (fr)
NL (1)	NL8901159A (fr)
SE (1)	SE8901660L (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5760000A (en) *	1994-05-13	1998-06-02	University Technologies International,Inc.	Inhibition of liver cancer by the use of GnRH and GnRH analogs
US6054432A (en) *	1996-09-12	2000-04-25	Asta Medica Aktiengesellschaft	Means for treating prostate hypertrophy and prostate cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4410514A (en) *	1982-12-06	1983-10-18	The Salk Institute For Biological Studies	GnRH Agonists
IT1178775B (it) *	1983-12-23	1987-09-16	Konzponti Valto Es Hitelbank R	Derivati della gonadoliberina e procedimento per la loro preparazione
HU189394B (en) *	1983-12-23	1986-06-30	Koezponti Valto- Es Hitelbank Rt Innovacios Alap,Hu	Method for producing spermatozoa suitable for fertilization from mature fishes
US4760053A (en) *	1984-08-02	1988-07-26	Fernand Labrie	Combination therapy for selected sex steroid dependent cancers
WO1986001105A1 (fr) *	1984-08-02	1986-02-27	Fernand Labrie	Composition pharmaceutique pour le traitement de cancers dependant d'hormones
HU193607B (en) *	1985-07-18	1987-11-30	Innofinance Altalanos Innovaci	Process for production of sexual products applyable for natural or artificial insemination for mammates
US4721775A (en) *	1985-08-26	1988-01-26	Board Of Regents, The University Of Texas System	Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
HU194913B (en) *	1986-01-03	1988-03-28	Innofinance Altalanos Innovaci	Process for producing novel gonadoliberin derivatives containing in the sixth position aromatic amino carboxylic acid and medical preparations containing these compounds

1988
- 1988-05-10 HU HU882347A patent/HU199694B/hu active IP Right Revival
1989
- 1989-04-18 IL IL89998A patent/IL89998A0/xx unknown
- 1989-05-08 CH CH1725/89A patent/CH678013A5/de not_active IP Right Cessation
- 1989-05-09 NL NL8901159A patent/NL8901159A/nl not_active Application Discontinuation
- 1989-05-10 LU LU87516A patent/LU87516A1/fr unknown
- 1989-05-10 GB GB8910724A patent/GB2218335B/en not_active Expired - Fee Related
- 1989-05-10 KR KR1019890006230A patent/KR900017610A/ko not_active Withdrawn
- 1989-05-10 BE BE8900499A patent/BE1004932A3/fr not_active IP Right Cessation
- 1989-05-10 GR GR890100315A patent/GR890100315A/el unknown
- 1989-05-10 JP JP1115265A patent/JPH0215097A/ja active Pending
- 1989-05-10 DE DE3915317A patent/DE3915317A1/de not_active Withdrawn
- 1989-05-10 SE SE8901660A patent/SE8901660L/ not_active Application Discontinuation
- 1989-05-10 DK DK228289A patent/DK228289A/da not_active Application Discontinuation
- 1989-05-10 FI FI892275A patent/FI892275A7/fi not_active Application Discontinuation
- 1989-05-10 FR FR8906094A patent/FR2631237A1/fr active Pending
- 1989-05-11 IT IT8920435A patent/IT1229251B/it active

Also Published As

Publication number	Publication date
HU199694B (en)	1990-03-28
IT1229251B (it)	1991-07-26
GB2218335A (en)	1989-11-15
FI892275A0 (fi)	1989-05-10
SE8901660D0 (sv)	1989-05-10
GB8910724D0 (en)	1989-06-28
JPH0215097A (ja)	1990-01-18
HUT49813A (en)	1989-11-28
NL8901159A (nl)	1989-12-01
BE1004932A3 (fr)	1993-03-02
KR900017610A (ko)	1990-12-19
IL89998A0 (en)	1989-12-15
DK228289D0 (da)	1989-05-10
SE8901660L (sv)	1989-11-11
IT8920435A0 (it)	1989-05-11
GB2218335B (en)	1991-09-25
FR2631237A1 (fr)	1989-11-17
GR890100315A (el)	1990-03-12
FI892275A7 (fi)	1989-11-11
DE3915317A1 (de)	1989-11-23
LU87516A1 (fr)	1990-12-11
DK228289A (da)	1989-11-11

Legal Events

Date	Code	Title	Description
1995-01-31	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
DE3750764T2 (de)	1995-06-29	Kontinuierliche verabreichung des luteinisierendes hormon abgebenden hormons in kombination mit sexsteroidverabreichung als empfängnisverhütungsmittel.
DE69327788T2 (de)	2000-06-21	Pharmazeutische zusammenstezungen zur hemmung von tumoren in verbindung mit prostaten adenokarzinom magenkrebs und brustkrebs
DE69509544T2 (de)	1999-09-02	Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE3486028T2 (de)	1993-08-19	Verabreichungsform von arzneimitteln.
DE69115247T2 (de)	1996-07-25	Behandlung von fettleibigkeit mit einem alpha-2-adrenergen-agonisten und einem wachstumshormon freigebenden peptid.
DE69824622T2 (de)	2009-09-24	Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
DE69214818T2 (de)	1997-02-27	LHRH-Antagonisten
EP0357978B1 (fr)	1992-05-13	Préparation pharmaceutique pour le traitement du diabète sucré
DE60315964T2 (de)	2008-05-15	Verbesserung der herstellung von endogenen gonadotropin
DE69433058T2 (de)	2004-06-03	Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren
LAMBERTS et al.	1979	The inability of bromocriptine to inhibit prolactin secretion by transplantable rat pituitary tumors: observations on the mechanism and dynamics of the autofeedback regulation of prolactin secretion
CH646139A5 (de)	1984-11-15	Oxytocin-derivate.
DE60132072T2 (de)	2008-12-11	Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten
DE69107306T2 (de)	1995-06-08	Kombinierte behandlung mit einem gnr-antagonisten und gnr zur regulierung der gonadotropinspiegel in säugetieren.
DE69831241T2 (de)	2006-03-23	Gonadotropin freisetzendes Hormon Antagonist
DE69418744T2 (de)	1999-11-11	Verwendung von Pregnanderivaten zur Behandlung von Tumoren
DE2708125C2 (fr)	1988-11-17
EP0083925B1 (fr)	1986-10-08	Méthode de traitement pour provoquer l'ovulation chez les brebis ou les génisses
CH678013A5 (fr)	1991-07-31
Watkins et al.	1975	L-Dopa effects on serum LH and prolactin in old and young female rats
DE69006032T2 (de)	1994-05-05	Verfahren zur behandlung von unfruchtbarkeit oder verminderter fruchtbarkeit bei erwachsenen männern und die verwendung von präparaten in diesem verfahren.
DE69901721T2 (de)	2003-01-09	Pharmazeutische zusammensetzungen basierend auf alpha-cyclodextrin zur oralen verabreichung von lh-rh analogen
EP0137294B1 (fr)	1989-04-26	Gonadolibérine et agonistes de gonadolibérine dans le traitement de maladies métaboliques, dues à un trop faible niveau de parathormone
KAHN et al.	1965	Factors modifying the stimulatory action of norethynodrel on the mammary gland
DE3780431T2 (de)	1993-02-25	Behandlungsverfahren mit synergistika.